We are a development stage company with intellectual property rights to novel therapeutic antibodies and chemically activated vaccines in all major markets. These rights have been developed from discoveries indicating the power of the immune system to use covalent bonding as the basis for synthesizing antibodies that neutralize and remove target antigens with efficacy and safety superior to conventional antibodies.
The two classes of therapeutic monoclonal antibodies (MAbs) being developed by Covalent, Inc are: (a) irreversible MAbs (iMAbs), which bind and neutralize the target antigen with virtually infinite affinity, (b) catalytic MAbs (cMAbs), which hydrolyze and destroy the target antigen in an enzyme-like manner. Covalent, Inc has proof-of-principle for superior efficacy and diminished side effects of the cMAbs/iMAbs compared to conventional MAbs that bind the target antigen reversibly with 1:1 stochiometry (see Figure below). Covalent's cMAbs/iMAbs are isolated from the innate immune repertoire that has developed by Darwinian evolution, and immunization with Covalent's electrophilic antigen analogs induces the synthesis of the cMAbs/iMabs adaptively.
PLATFORM TECHNOLOGY: Covalent is in a position to generate cMAbs/iMAbs to diverse antigen targets for development as immunotherapies. In addition, Covalent is developing the electrophilic antigen analogs as therapeutic and prophylactic vaccine for unmet medical needs.
Covalent invites partnerships and investment in generating therapeutic cMAbs/iMAbs on-demand, including cMAbs/iMAbs to antigenic targets with an established market (e.g. TNFalpha and other cytokines).
SEED PRODUCTS: Covalent has in hand: (a) candidate immunotherapeutic cMAbs to amyloid proteins for treating central nervous system and systemic amyloidosis, and (b) a candidate electrophilic vaccine for treating and preventing HIV infection.
Covalent invites partnerships and investment in further preclinical and clinical development of its seed products.
COMPANY HISTORY: Our intellectual property was developed by Sudhir Paul, PhD and his group under NIH funded projects at the University of Nebraska and the University of Texas. He serves as a Chief Scientist for the company and holds a professorship at the University of Texas. Stephanie Planque, PhD is co-inventor in company's patents. She serves as Principal Scientist, and she holds an assistant professorship at the same university. Our CEO, Richard Massey, PhD, has extensive corporate and scientific experience in the catalytic antibody field and development of immunodiagnostic reagents.
CONTACT: Richard Massey, PhD